Add a new comment

Value, Momentum and the Outlook for Market Neutral L/S

Momentum stocks experienced a correction since Pfizer announced their Covid-19 vaccine results early November. Performance has nonetheless stabilized over the course of March, as the rebound in Value stocks has been persistent and started to be shown in the Momentum risk factor.